Summit's data layer maps the entire patient acquisition funnel — from first intent signal through verified fulfillment — across the largest exclusive condition-confirmed cohort in healthcare.
Pharma brands spend over $30 billion annually on patient acquisition and DTC media in the United States. That spend flows through a fragmented ecosystem of vendors — data providers, identity vendors, clean rooms, lead gen platforms, landing page hosts, DSPs, attribution tools — each charging margins of 50–85% to bridge the last mile between a media impression and a converted patient.
The reason the margins are sustainable: no single vendor owns the full stack. Each layer is necessary, none of them are sufficient, and brands pay each one separately.
The patient-acquisition data that produces high-converting cohorts isn't aggregated — it's operationally generated by companies that ran condition-specific campaigns for years. Building it from scratch takes a decade and tens of millions of dollars. Acquiring it is rare because the asset rarely changes hands.
Meta, Google, and most major DSPs restrict pharma brands from advertising prescription drugs directly. Unbranded condition campaigns can run, but the legal sponsor must be a separate entity. Holding companies and pharma brands can't structurally be that sponsor for their own clients without standing up an independent operating company.
Every vendor in the stack has its own data model, its own consent framework, its own audit requirements, its own DSP relationships. Stitching them together requires engineering investment that no single layer alone justifies.
Exclusive data layer · proprietary identity protocol · in-house unbranded sponsor capability · full-stack campaign infrastructure.
A 20-year exclusive license (2026–2046) to a decade's worth of condition-specific patient acquisition data. 15.3M condition-confirmed records across diabetes, sleep apnea, obesity, cardiac, polypharmacy, and adjacent conditions.
THIIC — Tokenized Healthcare Identity Interchange Cryptography. Bilateral encryption protocol that enables data partnerships without any PII transit, without vendor middleware fees. Patent-pending. Production-deployed.
Summit operates as the legal sponsor of unbranded Meta and Google campaigns on behalf of pharma brands — a structurally separate entity that lets pharma brands access platforms they otherwise cannot.
End-to-end campaign infrastructure: audience exploration, identity matching, DSP activation, landing pages, dynamic qualifiers, lead management, brand page recreation, display creative, MLR workflow, attribution.
Licensing Summit's data isn't buying records. It's skipping the part where you spend 10 years and tens of millions of dollars trying to build them yourself.
The 15.3M record count is the headline. What makes the data exclusive is what's inside each record.
Every record originated from a real patient who self-identified on an unbranded condition campaign. First-party. Consent-based. De-identified per HIPAA Safe Harbor. The dataset is not a model, not a list purchase, not a probabilistic append. It's the operational output of a decade of condition-specific patient acquisition campaigns.
Each use case maps to a specific tier combination and campaign pattern. Summit configures the mix per the brand's commercial objective.
Reach diagnosed patients before the next claim. Verified condition + intent signal in T3 panel.
Activate patients whose new coverage just opened access to previously-unaffordable therapy.
Multi-year supply behavior with patient-level fill cadence on file. Activate at predicted refill or abandonment moments.
Identify patients on competitor therapies who match the switch profile. Comorbidity-aware, payer-aware.
166,464 prescriber NPIs linked to confirmed patient volume. Warm prescribers, not cold specialty codes.
Patients clinically qualified but blocked by insurance, authorization, or documentation. The audience access programs are built for.
Match Summit-seeded campaigns to downstream supply fulfillment. 140K+ T3 → T1 confirmed converts on file demonstrate funnel velocity.
Verified, consent-based, condition-confirmed records as training input for predictive models or seeds for lookalike expansion.
Summit's data isn't only a targeting asset — it's a media-spend multiplier. Every campaign that starts with Summit's audience costs less to run and converts more of what it touches.
The seed list defines who a campaign reaches. Most data vendors offer seeds that are modeled, inferred, or aggregated from claims. Summit's seed is real patients who already raised their hand on the condition.
DSP lookalike models built on post-conversion patient records produce dramatically tighter expansion than seeds built on behavioral proxies or claims data. Verified seed quality drives lookalike quality directly.
Summit-seeded traffic enters the funnel already condition-confirmed. The qualifier flow skips questions about attributes Summit already knows. Fewer questions, less drop-off, more qualified completions.
These aren't optimizations stacked together — they compound. Cheaper impressions reach more relevant patients, who convert at a higher rate through a shorter qualifier flow. The marketing math improves in three places at once, on the same campaign budget.
Summit isn't a vendor relationship that adds friction. It's a platform that compresses time, cost, and operational complexity.
Today, pharma brands stitch together 5–7 vendor relationships per major campaign. Summit replaces all of them with one integrated platform.
Summit Audience Segments works with brands, agencies, holding companies, and strategic partners across the full range of commercial structures. The right next step depends on what you're building.
The fastest path is a focused conversation about your target conditions, audience needs, and timeline. We'll scope a license structure and walk through match rates and cohort sizing.
Summit operates as the independent sponsor entity for unbranded campaign work that brand clients cannot run directly. Multi-brand relationships across the full data layer are available.
Summit's data is exclusive. The platform is operational. The protocol is proprietary. We're open to category exclusive, full exclusive, and partnership / rev-share structures depending on what you're building.